Following our recent BioTalk article, Ambient Scribing in the NHS: A Compliance Framework Suppliers Cannot Ignore (30 July 2026), a significant development has emerged that suppliers and NHS organisations should be aware of.

On 6 August 2026, the Health Services Safety Investigations Body ("HSSIB") announced the launch of a formal investigation into the use of ambient voice technology ("AVT") - AI-enabled tools that listen to clinical conversations and automatically generate documentation - in NHS hospitals. HSSIB is a fully independent arm's length body of the Department of Health and Social Care. Its core role is to carry out independent patient safety investigations across the NHS in England, with the aim of reducing patient harm. 

What has prompted the investigation?

HSSIB identified the need for this investigation through its insights process and stakeholder engagement.[1] It notes that AVT adoption is accelerating while the safety implications are not fully understood, that implementation activity has focused more strongly on efficiency benefits than patient safety risk, and that routes for reporting AI-related incidents are not yet mature enough to provide confidence that emerging risks are being identified.

What will the investigation examine?

With a focus on acute adult secondary care settings, HSSIB will seek to understand:

• how AVT has contributed, or may contribute, to patient harm;
• the patient safety risks associated with AVT; and
• how accountability for AVT safety is understood at both local and national levels.

The investigation's findings are expected to be published in Summer 2027. HSSIB is calling for input from patients, families, carers, and health and care professionals at investigations@hssib.org.uk.

HSSIB's recent investigation into digital health technology

This investigation follows HSSIB's recent report on electronic prescribing and medicines administration ("ePMA") in May 2026. That investigation found that national assurance mechanisms do not provide adequate oversight of compliance with digital clinical safety standards, and that safety learning is not reliably captured or shared through formal reporting routes. HSSIB made formal safety recommendations to the MHRA on medical device classification of ePMA software, to NHS England and the Department of Health and Social Care on national minimum safety standards and procurement assurance, and to the Care Quality Commission on oversight of compliance with digital clinical safety standards. Suppliers should expect HSSIB to apply a similarly rigorous lens to AVT.

What does this mean for AVT suppliers?

This investigation reinforces the importance of the compliance framework set out in our recent article here. Suppliers should ensure their products meet all applicable requirements, including medical device registration where applicable, clinical safety standards (DCB0129 and DCB0160), and data compliance obligations. Suppliers should also note that HSSIB will specifically examine how accountability for AVT safety is understood at local and national levels, which may have implications for how responsibility is allocated between suppliers and NHS organisations in contractual and governance arrangements.

Bird & Bird is monitoring the situation closely and will provide a further update once the investigation report is published. If you have any questions, please do not hesitate to get in touch.